November 2023

I chaired an online meeting for Eli Lilly
Honorarium £1215

I chaired a series of 2 webinars sponsored by Eli Lilly on their new agent Tirzepatide
Honorarium £1215

I spoke at a meeting for primary care staff on SGLT2 inhibitors organised by Astra Zeneca
Honorarium £650

October 2023

I spoke at a meeting for primary care staff on SGLT2 inhibitors organised by Boehringer Ingelheim
Honorarium £1255

I chaired a meeting on inpatient diabetes for Menarini
Honorarium £1250

Gave a talk about inpatient diabetes to our inpatient nurses for Astra Zeneca
Honorarium £893.75

Attended an advisory board meeting for a drug that has not yet been launched in the UK for Lilly
Honorarium £1552

Speaking at a conference for diabetes nurses on inpatient diabetes for Lilly
Honorarium £2700

September 2023

I gave a talk to local GP’s and primary carer staff for Astra Zeneca
Honorarium £812.50

I gave a talk for GP’s and primary care staff on SGLT2 inhibitors for Menarini
Honorarium £875

I attended an advisory board meeting for Lilly discussing a drug not yet launched in the UK
Honorarium £540

August 2023

I gave a two talks to GP practices on SGLT2 inhibitors for AstraZeneca.
Honorarium £650 each talk

July 2023

I gave a talk to a GP practice on SGLT2 inhibitors for AstraZeneca.
Honorarium £650

I gave a talk to the NNUH inpatient team on all things diabetes for AstraZeneca.
Honorarium £800

June 2023

I did a webinar on SGLT2 inhibitors for AstraZeneca.
Honorarium £825

I attended the American Diabetes Association Meeting – Menarini part funded this by sponsoring my trip.
Honorarium £3990

7/6/23 – I gave a talk to the heart failure nurses at NNUH – it included talking about SGLT2s.
AstraZeneca
Honorarium £650

13/6/23 – I chaired a webinar hosted by Menarini on CV risk reduction and CKD management.
Honorarium £600

14/6/23 – I gave a talk to a GP practice on CV risk reduction and the use of SGLT2 inhibitors.
AstraZeneca
Honorarium £650

March 2023

I gave a talk to a group of consultant colleagues and heart failure nurses on SGLT2s for AstraZeneca.
Honorarium £650

I filmed some educational videos for AstraZeneca on the use of SGLT2s, on NICE guideline NG28 and the use of SGLT2s in chronic kidney disease. Honorarium £1200

I gave a talk to GP’s and practice nurses on SGLT2 inhibitors for Boehringer Ingelheim.
Honorarium £840

I gave a talk to GP’s and practice nurses and chaired a meeting on SGLT2 inhibitors for AstraZeneca.
Honorarium £1800

February 2023

I was asked to speak for Abbott at the ATTD conference in Berlin. They paid for travel, accommodation and registration.
Honorarium £2850

I gave a webinar on inpatient diabetes technology for Novo Nordisk India.
Honorarium €720

January 2023

AstraZeneca
Honorarium £650

AstraZeneca
Honorarium £650

I have been asked to help set up a new website to allow diabetes teams to network – Diabetes MDT
Honorarium £5000

AstraZeneca
Honorarium £650

December 2022

Webinar sponsored by Boehringer Ingelheim.
Honorarium £200

AstraZeneca
Honorarium £650

November 2022

Webinar sponsored by Boehringer Ingelheim.
Honorarium £300

October 2022

I was asked to speak at an on-line meeting in the US on the use of ketones in managing diabetes.
Honorarium $1200

AstraZeneca
Honorarium £650

September 2022

Novo paid for travel, accommodation, subsistence and registration to the European Association for the Study of Diabetes meeting in Stockholm – 19-23 September 2022. I was also asked to chair a meeting they held.
Honorarium £1750

July 2022

I led an online webinar for Novo Nordisk to go through feedback and any lessons learnt from attending the American Diabetes Association meeting.
Honorarium £500

June 2022

Boehringer Ingelheim rep face to face meeting.

Registration, travel, accommodation and subsistence to the American Diabetes Association as well as honoraria to chair some meetings.
Honorarium £2000

AstraZeneca
Honorarium £650

AstraZeneca
Honorarium £650

AstraZeneca
Honorarium £650

May 2022

Lilly rep virtual meeting

Napp rep virtual meeting

Lilly medical advisors face to face meeting

Novo Nordisk rep virtual meeting

AstraZeneca
Honorarium £650

April 2022

Novo Nordisk – hosting a series of 3 meetings
Honorarium £630

AstraZeneca
Honorarium £650

AstraZeneca
Honorarium £650

March 2022

Lilly rep virtual meeting

AstraZeneca rep – Virtual Meeting

AstraZeneca – Honorarium £650

AstraZeneca – Honorarium £650

Planned talk for AstraZeneca cancelled but reduced honorarium provided for preparation time

Honorarium £300

February 2022

I gave 4 talks for AstraZeneca on the use of SGLT2 inhibitors

Honorarium £2000 (£500 Each Talk)

November 2021

I attended an advisory board meeting for Astra Zeneca

Honorarium £2500

Travel and accommodation provided by Novo Nordisk for a talk I gave at Diabetes Professional Care

Honorarium £765

September 2021

Attended a virtual meeting with Novo Nordisk

Honorarium £500

I did a speaker meeting for Boehringer-Ingelheim

Honorarium £550

I did a speaker meeting for Boehringer-Ingelheim

Honorarium £660

August 2021

I was part of an online panel as part of a webinar series on diabetes – entitled – DPC Summer Forum – ADA into Practice – Diet, Lifestyle, Behavioural Medicine & Mental Health

Honorarium £250

June 2021

Virtual presentation for Boehringer Ingelheim

Honorarium £770

Virtual presentation for Lilly

Honorarium £1540

Virtual meeting series for Novo

Honorarium £510

May 2021

Virtual presentation for Boehringer Ingelheim

Honorarium £612.50

April 2021

Virtual presentation for Novo Nordisk India on inpatient diabetes in the ICU

Honorarium £735

January 2021

Virtual presentation for Novo Nordisk

Honorarium £510

June 2020

Chairing a virtual meeting on Diabetes in the Elderly for Novo Nordisk.

Honorarium £600

Taking part in an educational event for Novo Nordisk sales representatives.

Honorarium £510

April 2020

Taking part in a webinar across Sub-Saharan Africa on the impact of COVID-19 on diabetes for Novo Nordisk.

Honorarium £1250

November 2019

Travel, accommodation and honorarium provided by Novo Nordisk to attend a Key Scientific Leaders meeting in Paris.

Honorarium £2660

October 2019

Travel and accommodation to attend as the National Lead for the Novo Nordisk sponsored FOCUS study – Birmingham.

June 2019

Travel and accommodation to attend as the local lead for the Novo Nordisk sponsored PIONEER and SOUL studies – Paris.

April 2019

Travel, accommodation and honorarium provided by Novo Nordisk to attend a Key Scientific Leaders meeting in Brussels.

Honorarium £5250

February 2019

Travel and accommodation to attend as the National Lead for the Novo Nordisk sponsored FOCUS study – Miami Florida.

January 2019

Travel and accommodation provided by Sanofi Diabetes to travel to Washington DC to be part of their FDA application team for sotagliflozin.

Honorarium £9750

December 2018

Travel, accommodation and honorarium provided by Novo Nordisk to attend a Key Scientific Leaders meeting in Madrid.

Honorarium £2890

Travel and accommodation provided by Sanofi Diabetes to travel to New Jersey to be part of their FDA application team for sotagliflozin.

Honorarium £6500

November 2018

Travel and accommodation provided by Sanofi Diabetes to travel to New Jersey to be part of their FDA application team for sotagliflozin.

Honorarium £7,250

August 2018

Travel and accommodation provided by Sanofi Diabetes to travel to New Jersey to be part of their FDA application team for sotagliflozin.

Honorarium £7,250

July 2018

Travel and accommodation provided by Sanofi Diabetes to travel to New Jersey to be part of their FDA application team for sotagliflozin.

Honorarium £7,250

May 2018

Travel and accommodation provided by European Wound Management Association to speak at their annual conference, Krakow.

Travel and accommodation provided by Malvern Foot Conference to speak at their bi-annual conference, Malvern

April 2018

Travel, accommodation and honorarium provided by Novo Nordisk to attend a Key Scientific Leaders meeting in Amsterdam.

Honorarium £5,500

March 2018

Travel and accommodation provided by European Vascular Society to speak at the 22^nd European Vascular Course, Maastricht.

January 2018

Travel and accommodation provided by Dr Shashank Joshi to speak at the 17^th International Symposium on Diabetes, Mumbai, India.

December 2017

Travel and accommodation provided by Novo Nordisk to attend and present a poster at the International Diabetes Federation meeting in Abu Dhabi

November 2017

Travel and accommodation provided by Sanofi Diabetes to attend an advisory board meeting in London.

Honorarium £1350

Travel, accommodation and honorarium provided by Novo Nordisk to attend a Key Scientific Leaders meeting in Berlin.

September 2017

Travel and accommodation provided by Novo Nordisk to attend and present a poster at the European Association for the Study of Diabetes meeting in Lisbon

Chairing a meeting for Eli Lilly on GLP-1 analogue use

Honorarium £600

So far this year I have also met pharmaceutical reps in my office from:

• Napp
• Novo-Nordisk
• Astra Zeneca
• Apodi

April 2017

Travel, accommodation and honorarium provided by Novo Nordisk to attend and speak at a Key Scientific Leaders meeting in Vienna.

Honorarium €4000

November 2016

Travel, accommodation and honorarium provided by Novo Nordisk to attend a Key Scientific Leaders meeting in Barcelona.

August 2016

Travel and honorarium to attend an internal event for Novo Nordisk for their Medical Affairs Leadership Academy.

Honorarium €750

May 2016

Travel and Accommodation to a Pioneer 6 investigators meeting in Washington DC provided by Novo Nordisk

April 2016

Travel for a meeting of the Joint British Diabetes Societies Inpatient Care Group to meet in London was funded by Diabetes UK

Travel, accommodation and honorarium provided by Novo Nordisk to attend and speak at a Key Scientific Leaders meeting in Paris

Honorarium £2000

Travel and accommodation provided by The Association of British Clinical Diabeteologists (ABCD) to attend the 1 day committee meeting and 1 day Annual Spring meeting of ABCD in Edinburgh.

Honorarium £250

Travel to speak at International Annual Scientific Meeting of the Association for Clinical Biochemistry and Laboratory Medicine in Warwick

I am on the clinical end point committee for Lexicon Pharmaceuticals on their trial on Sotagliflozin

Honorarium £50,000

October 2015

Travel and honorarium to speak at the Specsavers Professional Advancement Conference, Oslo, Copenhagen and Stockholm.

Honorarium £3,750

Travel, accommodation and honorarium provided by Novo Nordisk to attend and speak at a Key Scientific Leaders meeting in Berlin

Honorarium £1,500

September 2015

Travel to a research meeting provided by Novo Nordisk

Travel for a meeting of the Joint British Diabetes Societies Inpatient Care Group to meet in London was funded by Diabetes UK

June 2015

I spoke at an evening meeting for GP’s and practice nurses sponsored by AstraZeneca in Norwich on why I would not recommend the use of SGLT-2 inhibitors

Honorarium £500

Spoke at the 20^th annual Norfolk Respiratory Interest Group meeting, Norwich

Honorarium £250

April 2015

Travel and accommodation to attend the ‘Wound healing clinical development group’ in Amsterdam provided by Genentech.

Honorarium £4,400

December 2014

Travel and accommodation provided by Novo Nordisk to attend a Key Opinion Leaders meeting in Madrid.

November 2014

Travel to attend National Audit of Inpatient Diabetes Advisory group and ABCD committee meeting provided by those groups.

Travel and accommodation to attend a Dulaglutide Speaker training session in Vienna provided by Lilly.

Honorarium £1250

October 2014

Travel and honorarium to speak at the Specsavers Professional Advancement Conference, Birmingham.

Honorarium £500

September 2014

Travel and honorarium to attend a research sub-study meeting for Sanofi-Aventis in Birmingham

Honorarium £2760

June 2014

Travel and accommodation to San Francisco provided by Roche to attend a) the 5th meeting of the Blood Glucose Monitoring Performance Expert Panel and b) a round table meeting to meet with a team developing a new healing product for diabetic foot wounds at Genentech.

Honorarium $4000

May 2014

Travel and accommodation provided by The Association of British Clinical Diabeteologists (ABCD) to attend the 1 day committee meeting and 1 day Annual Spring meeting of ABCD in Edinburgh. I am the meetings secretary and on their executive. I organise their meetings.

Travel and accommodation provided by Novo Nordisk to attend a Key Opinion Leaders meeting in London.

March 2014

I spoke at an evening meeting for GP’s and practice nurses sponsored by Lilly and Boehringer Ingelheim in Great Yarmouth on Driving and Diabetes.

Honorarium £500

Travel provided by Diabetes UK to chair a session and speak at their national conference in Liverpool.

February 2014

Travel and accommodation provided to attend the 2nd Joint meeting of the Association of British Clinical Diabetologists and the Renal Association provided by ABCD.

January 2014

Travel costs to speak in London at the Royal Society of Medicine for the 3rd national diabetes inpatient conference, innovations in diabetes inpatient care provided by the RSM.

November 2013

Costs for travel to speak in Dublin at their annual meeting provided by the Irish Orthopaedic Anaesthetists Association.

I was taken for a meal by the regional sales manager for Novo Nordisk

Travel and accommodation provided by The Association of British Clinical Diabeteologists (ABCD) to attend the 1 day committee meeting and 1 day Annual Autumn meeting of ABCD in London. I am the meetings secretary and on their executive. I organise their meetings.

Speaking at the Specialist Registrar meeting of the Association of British Clinical Diabeteologists (ABCD).

Honorarium £250

October 2013

Travel to attend and speak at the Diabetes Inpatient Specialist Nurse UK Group meeting in London provided by the group.

Honorarium £100

Travel provided by the Cardio-renal forum for me to speak at their annual conference in London. The topic of my talk is: Do new diabetes drugs hold cardiovascular promise?

Honorarium £100

September 2013

My travel and accommodation to the Heels Trial and the Leukopatch trial meeting in Birmingham were paid for by The HTA and Reapplix.

Travel and accommodation provided to attend the 3 day Diabetic Foot Study Group meeting in Sitges, Spain. Funding for this is from the research funds generated by the work done in the diabetic foot clinic I lead at the Norfolk and Norwich Hospital.

Travel to attend Joint British Diabetes Society steering group meeting in London provided by Diabetes UK.

August 2013

Travel and accommodation provided to speak at the Jothydev Professional Educational Forum, Trivandrum, India by the Jothydev Diabetes Research Centre.

Honorarium of Rs 20,000 paid by P Jothydev Trust.

Also, to speak in Chennai, India on inpatient diabetes, travel and accommodation provided by Novo Nordisk (India).

No honorarium.

June 2013

Travel and accommodation provided by Novo Nordisk to attend the 5 day American Diabetes Association meeting in Chicago.

Travel for a meeting of the Joint British Diabetes Societies Inpatient Care Group to meet in London was funded by Diabetes UK.

Travel for a meeting of the editorial board of Practical Diabetes in London was paid for by the journal.

May 2013

Travel and accommodation provided by Novo Nordisk to attend a 2 day investigators meeting of the Leader Study in Prague. This is a phase 3b post marketing study comparing cardiovascular outcomes of people with diabetes and high risk of cardiovascular events given liraglutide vs placebo.

Travel and accommodation provided by Specsavers Finland to speak at their 1 day national Professional Advancement Conference in Helsinki. The topic of my lecture was: Diabetes related eye disease.

Honorarium €400

Travel and accommodation provided by Novo Nordisk to attend a 2 day ‘Key Scientific Leaders’ meeting in Madrid.

No honorarium.

April 2013

Travel and accommodation provided by The Association of British Clinical Diabeteologists (ABCD) to attend the 1 day committee meeting and 1 day Annual Spring meeting of ABCD in Solihull. I am the meetings secretary and on their executive. I organise their meetings.

March 2013

Travel provided by the Young Diabetologists Forum to speak at their national conference in Manchester. My lecture topic was: Peri-operative diabetes care.

No honorarium.

Travel provided by Diabetes UK to speak at their national conference in Manchester. My lecture topic was: JBDS Peri-operative Guidelines’ Impact on Elective Diabetes Care.

No honorarium.

I participated in an East Anglian Round Table meeting sponsored by Sanofi – Aventis discussing GLP–1 analogues, and Lixisenatide in particular.

Honorarium £400

February 2013

Travel provided by Sanofi Aventis to teach at the one day Young Diabetologists Forum in Manchester. My lecture topic was: Peri-operative diabetes care.

No honorarium.

I spoke at a Practice Nurse seminar at Spire Norwich Hospital. The topic of my talk was: Diabetes, your questions answered.

My honorarium was a box of chocolates.

January 2013

Travel and accommodation provided to attend a 2 day research meeting in Paris – sponsored by Urgo Laboratories, Paris. The foot clinic I lead at the Norfolk and Norwich Hospital is taking part in this multinational study examining the effect of a special wound dressing vs standard wound dressings

During 2014, I have met with representatives from the following companies, either in my office at the Norfolk and Norwich Hospital, or at local (L), national (N) or international (I) conferences.

• Genentec (N, I)
• Takeda (L)
• Lilly (L)
• Janssen (L)
• Abbott (L)
• Sanofi Aventis (L)
• Boehringer Ingelheim (L)
• Novo Nordisk (L)
• Roche (I)
• Astra-Zeneca (L)
• Merck, Sharpe, Dohme (L)

During 2013, I have met with representatives from the following companies, either in my office at the Norfolk and Norwich Hospital, or at local (L), national (N) or international (I) conferences

• Astra-Zeneca (L, N)
• Boehringer Ingelheim (L, N)
• Bristol Myers Squibb (L, N, I)
• Ferring (L)
• Eli Lilly (L, N, I)
• Janssen-Cilag / Johnson and Johnson (L, N)
• Merck, Sharpe, Dohme (L, N, I)
• Novo Nordisk (L, N, I)
• Pfizer (L, N)
• Prostrakan (L)
• Sanofi-Aventis (L, N, I)
• Takeda (L, N)